Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 price target. The analyst said there is still “plenty of time” before the Phase 3 MARITIME trial results are released, which means the “biggest source of debate” around Amgen will remain unresolved for now. The firm also note ...